New nasal spray for brain diseases passes first safety check in healthy volunteers
Knowledge-focused
Completed
This early-stage trial tested the safety and tolerability of a new nasal spray called CBT101 in 48 healthy men. Participants received either a single dose or multiple doses over several days. The study did not aim to treat any disease, but to gather initial safety data before tes…
Phase: PHASE1 • Sponsor: Ceres Brain Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC